This month, AAPM is spotlighting critical updates from the American Medical Association's Summary of the 2025 Medicare Physician Fee Schedule (MPFS) Final Rule and the introduction of the Mainstay New ICD-10 Code. These developments have [...]
The National Prescription Drug Take Back Day aims to provide a safe, convenient, and responsible means of disposing of prescription drugs, while also educating the general public about the potential for abuse of medications. Read [...]
AAPM joined other pain groups in protesting the proposed expansion of a CMS rule that would increase prior authorization requirements for implanted spinal neurostimulators to curb potential unnecessary utilization. Read more.
AAPM joined other pain groups in protesting the proposed expansion of a CMS rule that would increase prior authorization requirements for implanted spinal neurostimulators to curb potential unnecessary utilization. Full letter.
A new cross-sectional study uncovers shortcomings in pivotal trials supporting new drug applications for opioid analgesics, which range from study design to duration. Read more.
About 1 in 12 adults in the United States have high-impact chronic pain. Healthy People 2030 focuses on helping people with high-impact chronic pain safely manage their pain and reduce its impact. View chronic pain [...]
The free two-day virtual workshop, jointly organized by the National Center for Complementary and Integrative Health and the National Institute of Biomedical Imaging and Bioengineering at NIH, will take place online September 16–17. See Draft [...]
The new report details the recent evolution of the nation's opioid epidemic and physicians' progress toward ending it. AAPM Past President Steve Stanos, DO, represents the Academy on the Task Force. Key points from the [...]
The Centers for Disease Control and Prevention (CDC) recently announced an opportunity for stakeholders to share their individual perspectives on and experiences with pain and pain management, including but not limited to the benefits and [...]
FDA is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder (OUD) to add new recommendations about naloxone to the prescribing information. This will help ensure that health care [...]
© American Academy of Pain Medicine. All Rights Reserved | Privacy Policy | Media Resources
American Academy of Pain Medicine (AAPM) is a nonprofit 501(c)(6) tax-exempt organization.
